Evolution of bone metastases in patients receiving at least three months of checkpoint inhibitors.
E Gefard-GontierR MarkichM ZysmanR VeillonA DasteC DomblidesB SionneauM Gross-GoupilF LefortS PreyC DutriauxE GerardL DoussetA Pham-LedardM Beylot-BarryT SchaeverbekeMarie KostinePublished in: Cancer immunology, immunotherapy : CII (2022)
Bone response was observed in half of patients with available imaging and follow-up after 3 months of ICI treatment, with sclerosis observed in one-third of bone lesions at month 3, in all tumor types. Up to 20% of patients experienced a pseudoprogression of bone lesions such as previously described in primary tumor and other metastatic sites. Bone response was associated with improvement of pain and survival.
Keyphrases
- bone mineral density
- soft tissue
- bone loss
- end stage renal disease
- bone regeneration
- newly diagnosed
- small cell lung cancer
- chronic kidney disease
- chronic pain
- squamous cell carcinoma
- ejection fraction
- postmenopausal women
- dna damage
- high resolution
- pain management
- prognostic factors
- oxidative stress
- spinal cord injury
- combination therapy